Latest news with #PHR
Yahoo
6 days ago
- Business
- Yahoo
Q1 Earnings Outperformers: Phreesia (NYSE:PHR) And The Rest Of The Healthcare Technology for Providers Stocks
Looking back on healthcare technology for providers stocks' Q1 earnings, we examine this quarter's best and worst performers, including Phreesia (NYSE:PHR) and its peers. The healthcare technology industry focuses on delivering software, data analytics, and workflow solutions to hospitals, clinics, and other care facilities. These companies enable providers to streamline operations, optimize patient outcomes, and transition to value-based care models. They boast subscription-based revenues or long-term contracts, providing financial stability and growth potential. However, they face challenges such as lengthy sales cycles, significant upfront investment in technology development, and reliance on providers' adoption of new tools, which can be hindered by budget constraints or resistance to change. Over the next few years, the sector is poised for growth as providers increasingly prioritize digital transformation and efficiency in response to rising healthcare costs and patient demand for seamless care. Tailwinds include the growing adoption of AI-driven tools for patient engagement and operational improvements, government incentives for digitization, and the expansion of telehealth and remote patient monitoring. However, headwinds such as tightening hospital budgets, cybersecurity threats, and the fragmented nature of healthcare systems could slow adoption. The 6 healthcare technology for providers stocks we track reported a mixed Q1. As a group, revenues beat analysts' consensus estimates by 3.4% while next quarter's revenue guidance was 0.7% below. Amidst this news, share prices of the companies have had a rough stretch. On average, they are down 8.7% since the latest earnings results. Founded in 2005 to streamline the traditionally paper-heavy patient check-in process, Phreesia (NYSE:PHR) provides software solutions that automate patient intake, registration, and payment processes for healthcare organizations while improving patient engagement in their care. Phreesia reported revenues of $115.9 million, up 14.5% year on year. This print exceeded analysts' expectations by 0.6%. Overall, it was a strong quarter for the company with an impressive beat of analysts' EPS estimates and customer base in line with analysts' estimates. "Our fiscal year 2026 is off to a strong start. I am grateful to our team for their continued commitment to our mission, vision and values. I believe our performance is a reflection of our team truly living our values,' said CEO and Co-Founder Chaim Indig. The stock is down 2.2% since reporting and currently trades at $24.43. Is now the time to buy Phreesia? Access our full analysis of the earnings results here, it's free. Operating one of the largest healthcare group purchasing organizations in the United States with over 4,350 hospital members, Premier (NASDAQ:PINC) is a technology-driven healthcare improvement company that helps hospitals, health systems, and other providers reduce costs and improve clinical outcomes. Premier reported revenues of $261.4 million, down 8.9% year on year, outperforming analysts' expectations by 7.4%. The business had a very strong quarter with a solid beat of analysts' EPS estimates and an impressive beat of analysts' full-year EPS guidance estimates. Premier scored the biggest analyst estimates beat among its peers. The market seems happy with the results as the stock is up 10.8% since reporting. It currently trades at $22.75. Is now the time to buy Premier? Access our full analysis of the earnings results here, it's free. Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ:ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models. Astrana Health reported revenues of $620.4 million, up 53.4% year on year, falling short of analysts' expectations by 2.5%. It was a slower quarter as it posted revenue guidance for next quarter meeting analysts' expectations and full-year EBITDA guidance slightly missing analysts' expectations. Astrana Health delivered the fastest revenue growth but had the weakest performance against analyst estimates and weakest full-year guidance update in the group. As expected, the stock is down 24% since the results and currently trades at $25.38. Read our full analysis of Astrana Health's results here. Driven by the vision of an "Autonomous Pharmacy" with zero medication errors, Omnicell (NASDAQ:OMCL) provides medication management automation and adherence tools that help healthcare systems and pharmacies reduce errors and improve efficiency. Omnicell reported revenues of $269.7 million, up 9.6% year on year. This number surpassed analysts' expectations by 3.7%. Taking a step back, it was a slower quarter as it recorded full-year EBITDA guidance missing analysts' expectations. The stock is down 2.2% since reporting and currently trades at $29.83. Read our full, actionable report on Omnicell here, it's free. Founded in 2011 to transform how healthcare is delivered to patients with complex needs, Evolent Health (NYSE:EVH) provides specialty care management services and technology solutions that help health plans and providers deliver better care for patients with complex conditions. Evolent Health reported revenues of $483.6 million, down 24.4% year on year. This print topped analysts' expectations by 4.9%. Aside from that, it was a mixed quarter as it also recorded full-year revenue guidance slightly topping analysts' expectations but a significant miss of analysts' EPS estimates. Evolent Health pulled off the highest full-year guidance raise but had the slowest revenue growth among its peers. The stock is down 31.5% since reporting and currently trades at $7.38. Read our full, actionable report on Evolent Health here, it's free. As a result of the Fed's rate hikes in 2022 and 2023, inflation has come down from frothy levels post-pandemic. The general rise in the price of goods and services is trending towards the Fed's 2% goal as of late, which is good news. The higher rates that fought inflation also didn't slow economic activity enough to catalyze a recession. So far, soft landing. This, combined with recent rate cuts (half a percent in September 2024 and a quarter percent in November 2024) have led to strong stock market performance in 2024. The icing on the cake for 2024 returns was Donald Trump's victory in the U.S. Presidential Election in early November, sending major indices to all-time highs in the week following the election. Still, debates around the health of the economy and the impact of potential tariffs and corporate tax cuts remain, leaving much uncertainty around 2025. Want to invest in winners with rock-solid fundamentals? Check out our Top 5 Growth Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
PHR Q1 Earnings Call: Revenue Misses, Profitability Surges Amid Product Expansion
Healthcare technology company Phreesia (NYSE:PHR) missed Wall Street's revenue expectations in Q1 CY2025, but sales rose 14.5% year on year to $115.9 million. Its GAAP loss of $0.07 per share increased from -$0.35 in the same quarter last year. Is now the time to buy PHR? Find out in our full research report (it's free). Revenue: $115.9 million (14.5% year-on-year growth) EBITDA guidance for the full year is $87.5 million at the midpoint, above analyst estimates of $81.46 million Operating Margin: -2.8%, up from -19.2% in the same quarter last year Customers: 4,411, up from 4,341 in the previous quarter Market Capitalization: $1.48 billion Phreesia's first quarter saw continued sales growth, though revenue fell short of Wall Street expectations. Management highlighted the impact of products like appointment readiness, post-script engagement, and enhanced bill pay, while attributing year-on-year revenue growth primarily to an increase in average healthcare services clients and higher revenue per client. CEO Chaim Indig highlighted the measurable impact of these offerings on patient and provider outcomes. The company also attributed improved profitability to operating leverage from prior investments in its sales and marketing teams. CFO Balaji Gandhi emphasized that 'getting a really good return' on these early investments has been key to Phreesia's margin improvement, reflecting a more efficient expense structure even as product development remains a priority. Looking ahead, Phreesia's guidance is anchored by expectations for continued growth in its network and further margin expansion. Management expects new product modules and increased revenue per client to drive results for the remainder of the year, citing strong early traction from offerings like Medaphine and enhanced bill pay. Gandhi discussed the company's approach to capital allocation, noting a recently approved share repurchase program is an opportunistic tool meant to provide flexibility rather than signal a change in strategy. Indig noted that artificial intelligence is being incorporated across the organization, stating, 'AI is enabling us to do things within the Phreesia we are very excited for.' The company also anticipates ongoing positive free cash flow, though Gandhi cautioned that quarter-to-quarter improvements may vary depending on invoicing and capital expenditures. Management attributed the quarter's performance to broad-based product adoption, operational discipline, and the early impact of recently launched solutions. Product-led growth focus: Phreesia credits growth in patient engagement and bill pay modules for improved outcomes among healthcare clients. Indig highlighted that these solutions have already shown 'measurable impact' and are central to the company's strategy. AI integration underway: The company has started embedding artificial intelligence across its operations and product suite, aiming to deliver more scalable, efficient solutions. Indig explained that AI is 'allowing us to do things that we weren't able to do before,' though he noted customers ultimately value practical solutions over the technology itself. Network and provider expansion: Client numbers increased over the quarter, with Gandhi noting ongoing strength in both acquiring new customers and expanding business with existing ones. The company's approach emphasizes landing clients with potential for higher revenue and shorter payback periods. Operating leverage from prior investments: Improved margins were attributed to earlier investments in go-to-market functions. Gandhi described the current environment as one where Phreesia is now 'getting a really good return' on those investments, leading to greater efficiency. Early revenue from new offerings: The Medaphine platform, acquired last year, has begun contributing incremental revenue, though management described its monetization as still very early, characterizing it as 'in the first inning.' Enhanced bill pay continues to gain adoption, supporting transaction volume growth across the provider network. Management expects future performance to be driven by continued network growth, increased product adoption, and disciplined cost management. Incremental client and product expansion: Phreesia aims to grow its network by adding new healthcare clients and increasing average revenue per client through upselling additional modules and services. Management believes these efforts will support both top-line growth and operating leverage. AI-enabled product enhancements: The ongoing rollout of AI-powered features is expected to improve both the efficiency of Phreesia's solutions and the value delivered to customers. Indig emphasized that AI integration should drive 'massive value' for clients and support near-term returns for investors. Maintaining operational discipline: Gandhi stated that expense trends are expected to remain relatively flat, with continued focus on maximizing returns from prior investments. Management also anticipates ongoing positive free cash flow, though capital expenditures and working capital timing may cause fluctuations between quarters. In the coming quarters, key areas to watch will be (1) the uptake and monetization of new product modules like Medaphine and enhanced bill pay, (2) the pace of AI integration and its ability to drive tangible benefits for clients, and (3) sustained growth in client numbers and average revenue per customer. Execution on disciplined capital allocation, including opportunistic share repurchases, and further operating leverage will also be critical signposts for investors. Phreesia currently trades at a forward P/E ratio of 25.6×. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it's free). Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
Phreesia: Fiscal Q1 Earnings Snapshot
WILMINGTON, Del. (AP) — WILMINGTON, Del. (AP) — Phreesia Inc. (PHR) on Wednesday reported a loss of $3.9 million in its fiscal first quarter. On a per-share basis, the Wilmington, Delaware-based company said it had a loss of 7 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 13 cents per share. The developer of health care software posted revenue of $115.9 million in the period, also surpassing Street forecasts. Six analysts surveyed by Zacks expected $114.7 million. Phreesia expects full-year revenue in the range of $472 million to $482 million. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on PHR at
Qatar Tribune
18-05-2025
- Entertainment
- Qatar Tribune
The Voice of OFWs: DJ Meow, from airwaves icon to community leader
Darlene Regis He has an energy-infused, masculine DJ voice you've likely heard before — a familiar and warm presence on the airwaves that has become instantly recognizable across Qatar's Filipino community. You can catch him on Pinoy Heart Radio (PHR), spot him at media conferences, and see him in action during outreach programs and community events. He is a household name in the Filipino diaspora, popularly known as 'DJ Meow' — but behind the mic is Romeo Esmeria Villegas Jr., a man driven by passion, purpose, and people-first advocacy. DJ Meow has been a cornerstone of Overseas Filipino Workers (OFWs) in Qatar for over 16 years. As the PHR Founding Chairman, his passion for broadcasting and commitment to community service, creates a platform that resonates with the modern heroes in the Middle East and around the world. Why 'DJ Meow'? Where does the moniker come from? 'It's simple,' he laughs. 'It's from my name — RoMeo. I added a 'W' and it became DJ Meow. It's quirky, catchy, and easy to remember!' From Tambo Pamplona to Qatar's Airwaves Born in Manila, grew up in Bicol, and lived in Tambo Pamplona, Camarines Sur, DJ Meow's journey is a testament to humble beginnings and unwavering determination. 'I am the youngest in a brood of four,' he shares. 'Despite our financial challenges, I worked while studying to support my education, juggling jobs and studies that opened doors to opportunities abroad.' His perseverance paid off, leading him to Qatar, where he initially worked for an MEP company for eight years. 'The transition wasn't easy,' he admits. 'The cultural differences and strict work environment were challenging. But I endured, learned, and grew.' OFW by Day, DJ by Night While many recognize DJ Meow as the voice behind PHR's broadcasts, his primary profession is as a Document Controller and trainer. 'Managing records and ensuring document accuracy is my day job,' he explains. 'Being a DJ is my passion and a way to serve the Filipino community.' 'In 2013, we organized our very first Typhoon Relief Operation in Laguna for over 200 households, and as of now, we have completed 44 outreach programs — both here in Doha and in the Philippines,' he says. 'It started over 12 years ago as a small platform for Filipino voices and has now grown into a vital community hub,' he adds. Service with Recognition DJ Meow's contributions have not gone unnoticed. He's received multiple recognitions, including the Outstanding Leadership Award, Trainer of the Year, Plaque of Inspiring Change Award and Honors from the Philippine Embassy in Qatar, UFOQ, and AFJQ. 'These recognitions motivate me to continue serving our kababayans,' he says. Under his leadership, PHR was nominated for the 2021 Presidential Awards for Filipino Individuals and Organizations Overseas by the Commission on Filipinos Overseas under the Office of the President of the Philippines. Exclusive Interview with Qatar Tribune What inspired you to start Pinoy Heart Radio? I wanted to create a platform where Filipinos could feel at home, share their stories, and support each other. PHR was born out of that desire. How do you balance both careers? It's all about passion and purpose. I work all day and serve the community at night. What are some memorable events you've led? Feeding programs, free medical missions, concerts like Parokya ni Edgar and Gloc 9, and outreach during Philippine Independence Day. What's your favorite moment on air? When listeners send messages saying our shows uplift them or our charities helped their families. That's the real reward. What message do you have for fellow Filipinos in Qatar? Never give up. Help others even when you know they can't help you back. That's true service. Looking Ahead As DJ Meow continues to juggle his roles, he remains committed to his mission. 'I'm just happy with what I'm doing right now,' he says. 'If I can make someone's day better through music or kindness, then I've done my part.' His legacy? 'Just to be remembered as a simple, friendly person who used his voice and heart to uplift others,' he concludes. Whether through airwaves, events, or acts of service, Romeo Villegas Jr. – DJ Meow – has built more than just a name. He's built a bridge between hearts in Qatar and the Philippines, one broadcast at a time.
Yahoo
29-04-2025
- Business
- Yahoo
1 Cash-Heavy Stock with Impressive Fundamentals and 2 to Ignore
Companies with more cash than debt can be financially resilient, but that doesn't mean they're all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers. Just because a business has cash doesn't mean it's a good investment. Luckily, StockStory is here to help you separate the winners from the losers. That said, here is one company with a net cash position that can continue growing sustainably and two with hidden risks. Net Cash Position: $8.30 million (0.2% of Market Cap) Founded in 1914 and evolving through more than a century of industrial innovation, Brady (NYSE:BRC) manufactures and supplies identification solutions and workplace safety products that help companies identify and protect their premises, products, and people. Why Are We Hesitant About BRC? Organic revenue growth fell short of our benchmarks over the past two years and implies it may need to improve its products, pricing, or go-to-market strategy Subscale operations are evident in its revenue base of $1.42 billion, meaning it has fewer distribution channels than its larger rivals 1.8 percentage point decline in its free cash flow margin over the last five years reflects the company's increased investments to defend its market position At $69.89 per share, Brady trades at 14.4x forward price-to-earnings. Check out our free in-depth research report to learn more about why BRC doesn't pass our bar. Net Cash Position: $66.42 million (4.6% of Market Cap) Founded in 2005 to streamline the traditionally paper-heavy patient check-in process, Phreesia (NYSE:PHR) provides software solutions that automate patient intake, registration, and payment processes for healthcare organizations while improving patient engagement in their care. Why Are We Cautious About PHR? Revenue base of $419.8 million puts it at a disadvantage compared to larger competitors exhibiting economies of scale Negative free cash flow raises questions about the return timeline for its investments Negative returns on capital show that some of its growth strategies have backfired Phreesia's stock price of $24.49 implies a valuation ratio of 28.9x forward price-to-earnings. To fully understand why you should be careful with PHR, check out our full research report (it's free). Net Cash Position: $350.5 million (6.1% of Market Cap) Headquartered in Israel, Nova (NASDAQ:NVMI) is a provider of quality control systems used in semiconductor manufacturing. Why Is NVMI a Good Business? Annual revenue growth of 24.5% over the past five years was outstanding, reflecting market share gains this cycle Free cash flow margin jumped by 12.3 percentage points over the last five years, giving the company more resources to pursue growth initiatives, repurchase shares, or pay dividends Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures Nova is trading at $193.54 per share, or 25.7x forward price-to-earnings. Is now a good time to buy? Find out in our full research report, it's free. Market indices reached historic highs following Donald Trump's presidential victory in November 2024, but the outlook for 2025 is clouded by new trade policies that could impact business confidence and growth. While this has caused many investors to adopt a "fearful" wait-and-see approach, we're leaning into our best ideas that can grow regardless of the political or macroeconomic climate. Take advantage of Mr. Market by checking out our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years. Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Axon (+711% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
